Novartis
NVS
NVS
1,180 hedge funds and large institutions have $15.2B invested in Novartis in 2023 Q1 according to their latest regulatory filings, with 97 funds opening new positions, 353 increasing their positions, 498 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
1,180
Holders Change
-2
Holders Change %
-0.17%
% of All Funds
18.89%
Holding in Top 10
14
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.69%
% of All Funds
0.22%
New
97
Increased
353
Reduced
498
Closed
73
Calls
$564M
Puts
$226M
Net Calls
+$338M
Net Calls Change
-$119M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$255M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$114M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$102M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$94.3M |
| 5 |
Millennium Management
New York
|
+$85.9M |
Top Sellers
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$399M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$363M |
| 3 |
Two Sigma Advisers
New York
|
-$98.8M |
| 4 |
Primecap Management
Pasadena,
California
|
-$70.6M |
| 5 |
MSE
MUFG Securities EMEA
London,
United Kingdom
|
-$55.1M |
